Negative hyperselection of patients with RAS wild-type metastatic colorectal cancer for panitumumab: A biomarker study of the phase III PARADIGM trial.
Kohei Shitara(National Cancer Center Hospital East), Takayuki Yoshino(University of Tsukuba), Hisatsugu Ohori(Tohoku University Hospital), Katsuya Tsuchihara(Chiba Cancer Center), Takeo Sato(Kitasato University), Hiroyuki Uetake(National Hospital Organization), Kiwamu Akagi(Kuwait University), Atsushi Ochiai(Tokyo University of Science), Kentaro Yamazaki(Shizuoka Cancer Center), Yoshito Komatsu(Hokkaido University Hospital), Manabu Shiozawa(Kanagawa Prefectural Hospital Organization), Eiji Oki(Kyushu University), Kei Muro(Aichi Cancer Center), Takeshi Kato(Osaka National Hospital), Kouji Yamamoto(Yokohama City University), Hirofumi Yasui(Shizuoka Cancer Center), Takeshi Naito(Kitasato University), Jun Watanabe(Yokohama City University Medical Center), Riu Yamashita(National Cancer Center Hospital East), Junpei Soeda(Takeda (Japan))
Cited by 35
Related Papers
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k